The Medical Breakthrough
Asherman’s syndrome is a condition where the uterine cavity is obstructed by severe adhesions (scar tissue), often leaving women with no reproductive options other than surrogacy or adoption. This treatment is part of an ongoing clinical trial at SGRH, which has enrolled 10 patients so far.
Key Highlights of the Procedure
- Source of Cells: Mesenchymal stem cells were derived from Wharton’s jelly of the umbilical cord. This source is preferred due to its high regenerative potential and low risk of immune rejection.
- Technique: Unlike previous global studies that used physical “scaffolds” or biomaterials, the SGRH team, led by Dr. Abha Majumdar, injected the stem cells directly into the basal layer of the endometrium under hysteroscopic guidance.
- Regenerative Effects: The therapy successfully increased endometrial thickness, improved menstrual flow, and reduced intrauterine adhesion scores, creating a receptive environment for embryo implantation.
Successful Case Studies
| Patient Profile | Condition Background | Outcome |
| 39-year-old woman | Severe adhesions after miscarriage treatment. | Delivered a healthy male baby (2.0 kg) at 35 weeks. |
| 40-year-old woman | Recurrent pregnancy loss and severe adhesions. | Delivered a healthy female baby (1.8 kg) via LSCS at 31 weeks. |
Why It Matters
For women in India, where surrogacy is strictly regulated, this regenerative approach offers a vital alternative for biological motherhood.
- First in India: This is the first reported successful use of this specific “sub-endometrial injection” technique in the country.
- Simplified Treatment: By avoiding complex biomaterials, the procedure is technically simpler and potentially more scalable for other medical centers.
Leave a Reply